west
nile
viru
wnv
posit
sens
singlestrand
rna
viru
member
genu
flavivirus
famili
flavivirida
natur
bird
sylvat
reservoir
wnv
endem
cycl
primari
vector
mosquito
viru
wide
spread
africa
middl
east
russia
sinc
outbreak
new
york
wnv
spread
east
west
state
north
america
transmiss
viru
human
via
mosquito
caus
signific
health
problem
west
nile
fever
neuroinvas
diseas
unfortun
antivir
vaccin
current
avail
therefor
effici
safe
antivir
urgent
need
kb
genom
wnv
singl
open
read
frame
translat
one
polypeptid
order
process
structur
nonstructur
protein
viral
proteas
mediat
posttransl
modif
polyprotein
cytoplasm
host
proteas
endoplasm
reticulum
wnv
replic
variou
type
cell
tissu
cultur
includ
vero
bhk
insect
cell
line
replic
host
cell
may
show
cytopath
effect
cpe
apoptosi
wnv
infect
induc
apoptosi
sever
differ
cell
line
includ
insect
cell
mammalian
cell
possibl
bax
gene
develop
assay
high
throughput
ht
screen
platform
wnv
follow
path
similar
number
virus
focu
cellbas
replicon
report
assay
biochem
assay
wnv
replicon
creat
harbor
luciferas
gfp
alon
replicon
luciferas
neor
report
replicon
adapt
format
assay
valid
known
inhibitor
wnv
first
ht
screen
wnv
consist
divers
set
compound
triaryl
pyrazolin
identifi
inhibitor
viral
rna
synthesi
anoth
studi
small
librari
compound
pyrolizin
identifi
may
inhibit
rna
synthesi
gu
et
al
publish
screen
librari
small
molecul
compound
wnv
replicon
luciferas
neor
report
also
develop
counterscreen
format
live
viru
employ
screen
compound
screen
sever
candid
compound
identifi
one
class
pyrazolopyrimidin
show
promis
activ
select
well
promis
followup
chemistri
develop
cell
base
assay
use
wnv
strain
format
build
prior
success
live
viral
ht
screen
influenza
viru
sar
cov
assay
employ
cell
viabil
end
point
use
promega
produc
luminesc
signal
relat
quantiti
atp
host
cell
directli
relat
cell
viabil
contrast
dye
format
dyeuptak
method
low
dynam
rang
assay
show
higher
dynam
rang
less
background
implement
wnv
assay
format
screen
compound
divers
group
small
molecul
target
variou
specif
step
viru
replic
discov
screen
campaign
optim
assay
robust
reproduc
ht
data
explor
assay
media
number
cell
per
well
multipl
infect
moi
incub
time
postinfect
test
complet
dmem
meme
without
nonessenti
amino
acid
neaa
meme
reduc
gl
find
signific
differ
among
three
meme
base
media
regard
luminesc
data
shown
howev
cytopath
effect
cpe
evid
cell
grown
infect
wnv
meme
dmem
signal
viru
control
dmem
show
higher
luminesc
signal
meme
luminesc
cell
control
ident
figur
meme
media
also
shorten
assay
incub
period
two
day
compar
dmem
media
henc
chosen
ht
test
moi
plate
wit
signific
differ
cell
viabil
differ
moi
figur
valu
moi
test
confirm
develop
robust
assay
efficaci
posit
control
compound
mycophenol
acid
mpa
vari
depend
infecti
dose
moi
mpa
show
protect
without
decreas
valu
base
find
develop
optim
condit
describ
materi
method
primari
screen
compound
librari
final
concentr
conduct
use
format
valu
rang
median
averag
sb
sn
plate
rang
mean
standard
deviat
figur
figur
statist
valu
indic
assay
provid
high
qualiti
requir
robust
reproduc
ht
assay
assay
overal
averag
inhibit
standard
deviat
control
drug
mpa
show
inhibit
averag
percent
inhibit
cutoff
repres
viral
mean
three
standard
deviat
common
method
statist
defin
hit
singl
dose
screen
use
cutoff
method
compound
identifi
activ
wnv
inhibitor
figur
confirm
activ
test
cytotox
top
inhibitori
compound
evalu
dose
respons
assay
use
ident
screen
secondari
assay
reveal
compound
dose
depend
respons
fifteen
compound
show
valu
less
three
compound
howev
cytotox
low
valu
rang
remain
compound
gave
valu
greater
tabl
ten
compound
show
select
index
ratio
evalu
tabl
compound
select
primari
dose
respons
screen
resuppli
supplier
solid
form
except
compound
avail
time
tabl
time
addit
assay
conduct
dose
respons
format
compound
serial
dilut
compound
ad
vero
cell
h
postinfect
luminesc
data
calcul
obtain
valu
compound
time
point
addit
seventeen
compound
show
valu
less
compound
activ
interestingli
compound
show
signific
chang
time
addit
figur
similar
pattern
seen
posit
control
mpa
mpa
within
rang
regardless
ad
contrast
compound
show
dramat
chang
accord
time
addit
figur
show
minor
chang
remain
six
compound
categori
show
valu
compound
ad
h
postinfect
valu
compound
class
less
compound
deliv
prior
h
postinfect
classifi
compound
accord
pattern
chang
valu
shown
tabl
figur
result
time
addit
assay
led
us
examin
proteas
potenti
target
hit
compound
proteas
import
enzym
respons
matur
viral
protein
earli
stage
replic
viru
host
cell
test
compound
inhibitori
activ
proteas
use
fret
base
vitro
enzymat
assay
result
identifi
inhibitori
effect
proteas
suggest
molecular
target
two
compound
may
wnv
figur
also
test
nphenylanthranil
acid
inhibitori
activ
moieti
common
two
compound
could
detect
signific
activ
system
data
shown
final
employ
titer
reduct
assay
confirm
antivir
activ
seven
compound
confirm
assay
titer
progeni
viru
produc
presenc
compound
measur
format
infect
vero
cell
use
moi
result
around
two
day
postinfect
treatment
infect
cell
compound
decreas
progeni
titer
fold
figur
exampl
show
inhibit
follow
inhibit
respect
concentr
potent
assay
least
activ
posit
control
drug
mpa
work
extrem
well
potent
inhibitor
assay
titer
reduct
assay
confirm
antivir
activ
hit
compound
select
pathway
figur
herein
report
discoveri
sever
new
chemotyp
ht
screen
compound
librari
inhibit
wnv
replic
tabl
endpoint
develop
employ
ht
screen
cpe
caus
viral
replic
advantag
target
base
ht
cpe
base
antivir
screen
expect
elucid
wider
rang
antivir
compound
target
base
assay
cpe
base
assay
like
discov
cytotox
compound
sinc
cytotox
compound
decreas
endpoint
signal
read
inact
advantag
reporterbas
assay
read
fals
posit
fact
found
compound
less
among
compound
subject
dose
respons
assay
pathway
probe
discoveri
depict
figur
top
compound
base
inhibitori
activ
examin
dose
respons
cytotox
assay
twentyfour
compound
show
dose
respons
inhibit
evalu
time
addit
assay
titer
reduct
assay
final
seven
compound
present
antiwnv
probe
hit
rate
secondari
assay
final
confirm
compound
compound
compound
respect
categor
compound
chemic
group
base
chemic
structur
tabl
first
group
uridin
deriv
full
chemic
structur
disclos
similar
compound
known
wnv
antivir
activ
second
group
compos
redox
also
activ
flavivirus
inhibitori
activ
dihydroorot
dehydrogens
third
group
compound
new
chemotyp
antiflaviviru
activ
shown
activ
ht
assay
nfkb
induct
inhibit
assay
aid
http
pubchemncbinlmnihgov
seven
compound
screen
time
addit
experi
confirm
antiwnv
activ
base
titer
reduct
assay
valu
suggest
ht
follow
assay
effect
method
probe
discoveri
evalu
none
compound
show
antiwnv
activ
good
posit
control
drug
mpa
howev
mechan
mpa
specif
viru
make
probe
identifi
signific
interest
time
addit
analysi
show
interest
pattern
valu
studi
suggest
possibl
target
compound
show
two
type
pattern
chang
accord
time
addit
compound
minim
chang
compound
increas
mpa
reflect
first
pattern
nucleosid
deriv
produc
second
pattern
suggest
compound
chang
may
target
host
chang
target
viru
identifi
one
compound
inhibit
viral
proteas
vitro
time
addit
studi
result
suggest
might
target
viral
proteas
exhibit
low
activ
primari
dose
respons
time
addit
assay
work
wnv
perform
follow
cdc
guidelin
vero
cell
atcc
crl
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
mm
lglutamin
wnv
strain
use
assay
propag
complet
minimum
essenti
medium
eagl
meme
media
obtain
sigmaaldrich
st
loui
usa
supplement
fb
unitsml
penicillin
streptomycin
mm
lglutamin
viru
stock
divid
ml
aliquot
store
viru
plaqu
form
unit
measur
use
agar
overlay
method
describ
previous
minor
modif
primari
ht
screen
two
compound
set
use
total
compound
southern
research
institut
sri
proprietari
compound
librari
compos
compound
select
compound
nation
institut
health
molecular
librari
screen
network
librari
compound
activ
previou
screen
bluetongu
viru
http
pubchemncbinlmnihgovassayassaycgi
loceara
sri
proprietari
librari
consist
histor
uniqu
compound
design
synthes
sri
mani
year
potenti
drug
candid
member
collect
high
biolog
relev
particularli
cancer
infecti
diseas
major
class
compound
repres
collect
includ
nucleosid
purin
pyrimidin
pteridin
imidazol
pyridin
quinolin
triazin
disaccharid
guanidin
urea
carbam
stock
concentr
compound
set
mm
dmso
singl
dose
primari
screen
stock
compound
dilut
solut
use
biomek
fx
give
work
concentr
dmso
aliquot
work
concentr
plu
addit
assay
media
transfer
well
control
stock
prepar
assay
media
fold
higher
target
concentr
dmso
cell
viral
control
mycophenol
acid
mpa
dmso
posit
control
mpa
purchas
sigmaaldrich
co
st
loui
usa
solubil
dmso
mgml
stock
concentr
control
ad
separ
assay
plate
aliquot
via
biomek
fx
addit
cell
viru
final
test
concentr
compound
mpa
final
dmso
well
maximum
allow
assay
review
data
primari
screen
compound
select
doserespons
studi
compound
stock
mm
dmso
use
select
compound
lowvolum
plate
dose
respons
plate
prepar
use
stackedpl
format
use
dilut
seri
total
ten
concentr
use
format
entir
plate
repres
one
ten
concentr
dilut
seri
aliquot
serial
dilut
plate
transfer
assay
plate
along
equal
volum
separ
transfer
control
addit
cell
viru
final
test
concentr
dose
respons
screen
dmso
vero
cell
suspend
complet
meme
cellsml
dispens
black
clearbottom
tissu
cultur
treat
plate
cellswel
use
matrix
matrix
thermofish
plate
cell
maintain
overnight
activ
humidifi
incub
test
compound
transfer
per
well
final
dmso
concentr
see
plate
consist
well
repres
cell
control
well
viru
control
well
posit
control
mpa
well
test
individu
compound
cell
plate
transfer
infect
addit
wnv
suspens
pfuml
complet
meme
use
matrix
plate
incub
h
promot
viru
replic
promega
madison
wi
ad
well
use
matrix
wellmat
incub
room
temperatur
min
luminesc
measur
use
perkin
elmer
envis
plate
reader
wellesley
integr
time
cytotox
antivir
efficaci
perform
doserespons
format
parallel
compound
serial
dilut
complet
media
meme
dmso
final
concentr
ad
cell
plate
ident
stack
plate
method
ten
point
twofold
dilut
seri
compound
concentr
rang
use
assay
viru
moi
media
ad
antivir
effect
cytotox
respect
plate
incub
h
incub
cell
viabil
measur
state
serial
dilut
compound
also
use
time
addit
studi
ad
infect
cell
plate
h
postinfect
wnv
moi
plate
develop
h
infect
valu
calcul
time
addit
point
valu
employ
evalu
assay
robust
calcul
deviat
cell
control
standard
deviat
viru
control
mean
cell
control
signal
minu
mean
viru
control
signal
signalbackground
sb
calcul
mean
cell
control
signal
divid
mean
viru
control
signal
signalnois
sn
calcul
mean
cell
control
signal
minu
mean
viru
control
signal
divid
standard
deviat
cell
control
signal
minu
standard
deviat
viru
control
signal
effect
concentr
drug
inhibit
cell
death
presenc
viru
cytotox
drug
alon
calcul
use
activitybas
softwar
idb
inc
guildford
uk
cpe
inhibit
cell
viabil
calcul
describ
elsewher
standard
curv
analysi
function
use
calcul
inhibitori
concentr
valu
proteas
titer
reduct
assay
recombin
proteas
express
purifi
ecoli
cofactor
residu
fluoresc
reson
energi
transfer
fret
base
assay
kit
purchas
anaspec
inc
ca
usa
follow
assay
protocol
publish
line
pubchem
univers
pittsburgh
molecular
librari
screen
center
http
wwwncbinlmnihgov
assay
perform
format
ngwell
enzym
compound
show
specif
inhibitori
effect
viru
replic
step
valid
efficaci
use
reduct
assay
vero
cell
seed
plate
volum
ml
incub
overnight
next
day
media
aspir
cell
infect
adsorpt
wnv
moi
one
hour
media
aspir
viru
wash
cell
phosphat
buffer
salin
media
replenish
contain
compound
variou
concentr
plate
incub
h
progeni
viru
titer
measur
assay
plate
format
well
per
dilut
viru
reagent
employ
determin
cell
death
sign
infect
well
luminesc
signal
less
mean
noninfect
control
signal
minu
time
standard
deviat
control
regard
posit
infect
calcul
number
posit
infect
neg
infect
reedmuench
method
summari
report
approach
develop
use
ht
screen
discov
specif
effect
antiwnv
probe
result
ht
secondari
assay
identifi
compound
specif
effect
antiwnv
probe
optim
compound
need
develop
effect
antivir
treatment
wnv
infect
addit
compound
identifi
serv
novel
molecular
probe
help
us
understand
biolog
wnv
futur
studi
focu
compound
target
viru
replic
mechan
action
conclus
identif
previous
known
novel
moieti
screen
librari
proof
wnv
assay
effect
ht
screen
